A patient receives 4 mg/kg of sugammadex to reverse moderate neuromuscular blockade at the conclusion of a general anesthetic. Which of the following is most likely to occur?

Approval in the United States of sugammadex for reversal of neuromuscular blockade was delayed in part because of concerns that it would lead to an increase in clinical bleeding. Numerous obser- vations had noted an increase in prothrombin and partial thrombo-plastin times associated with the administration of sugammadex. Subsequent clinical trials were carried out in a variety of surgical models to further elucidate this problem. No increase in clinical bleeding could be documented, and sugammadex was licensed for use in the United States in late 2015. Many anesthesiologists have now incorporated it into their practice.

To better understand the influence of sugammadex on tests of coagulation function, a team of German...

You do not currently have access to this content.